THOR-2 Cohort 3 interim analysis: erdafitinib in intermediate-risk NMIBC with FGFR3/2 alterations VJOncology 1:27 1 year ago 139 Далее Скачать
Update on First Biomarker-Directed Trial of Non-Muscle-Invasive Bladder Cancer Breakthroughs for Physicians 11:35 2 years ago 242 Далее Скачать
Personalizing Bladder Cancer Care in the Modern Therapeutic Era PeerView Oncology 1:01:13 1 year ago 1 866 Далее Скачать
